ADSTILADRIN

Ferring Pharmaceuticals🇺🇸 United States

FDA Page

Effective Date: Mar 24, 2026
Approval ID: 5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa
Products: 1 registered
Version: 15

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use ADSTILADRIN safely and effectively. See full prescribing information for ADSTILADRIN. ADSTILADRIN (nadofaragene firadenovec-vncg) suspension, for intravesical use Initial U.S. Approval: 2022

Quick Stats

Total Products1

Labelers3

Label Sections31

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.